Bafna Pharmaceuticals has reported a widening of its standalone net loss to Rs 2.08 crore for the quarter ended March 31, 2012 as compared to a net loss of Rs 0.85 crore over the same period previous fiscal. However, the net sales of the company increased by 10.57% to Rs 32.73 crore in the quarter under review from Rs 29.60 crore in same period year ago.
For the full year, the company’s net profit declined by 38.05% at Rs 20.74 crore against Rs 33.48 crore for the previous fiscal however, net sales of the company rose 19.43% to Rs 120.98 crore for FY12 from Rs 101.30 crore for FY11.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1652.00 |
| Dr. Reddys Lab | 1235.00 |
| Cipla | 1212.95 |
| Zydus Lifesciences | 920.00 |
| Lupin | 2316.10 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: